Ieq Capital LLC Purchases 5,498 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

• Ieq Capital LLC increased its holdings in Intuitive Surgical by 25.2%, purchasing an additional 5,498 shares, bringing their total to 27,325 shares valued at approximately $13.5 million.
• Intuitive Surgical's stock has seen a 0.7% decline, trading at $471.15 with a market cap of $168.90 billion, despite reporting a quarterly profit of $2.19 EPS, surpassing analyst expectations.
• Wall Street analysts are generally optimistic about Intuitive Surgical, with an average price target of $595.95 and 13 analysts rating the stock as a Buy.

Ieq Capital LLC increased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 25.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,325 shares of the medical equipment provider's stock after buying an additional 5,498 shares during the period. Ieq Capital LLC's holdings in Intuitive Surgical were worth $13,533,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of ISRG. Brighton Jones LLC boosted its holdings in Intuitive Surgical by 24.9% in the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock valued at $1,916,000 after purchasing an additional 731 shares during the period. Bank Pictet & Cie Europe AG boosted its holdings in Intuitive Surgical by 0.5% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 190,969 shares of the medical equipment provider's stock valued at $99,678,000 after purchasing an additional 883 shares during the period. AQR Capital Management LLC boosted its holdings in Intuitive Surgical by 14.9% in the 4th quarter. AQR Capital Management LLC now owns 33,592 shares of the medical equipment provider's stock valued at $17,534,000 after purchasing an additional 4,365 shares during the period. Voleon Capital Management LP bought a new stake in Intuitive Surgical in the 4th quarter valued at $5,368,000. Finally, Kapitalo Investimentos Ltda bought a new stake in Intuitive Surgical in the 4th quarter valued at $52,000. 83.64% of the stock is owned by institutional investors.

Intuitive Surgical Stock Down 0.7%

Shares of Intuitive Surgical stock opened at $471.15 on Thursday. The stock has a market capitalization of $168.90 billion, a P/E ratio of 65.71, a price-to-earnings-growth ratio of 4.97 and a beta of 1.59. The company has a 50-day simple moving average of $501.89 and a 200 day simple moving average of $519.66. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The firm's revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter last year, the company posted $1.78 EPS. On average, equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ISRG. UBS Group increased their price target on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Royal Bank Of Canada restated an "outperform" rating and issued a $615.00 price objective on shares of Intuitive Surgical in a research note on Tuesday, August 19th. Wall Street Zen upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. BTIG Research increased their price objective on shares of Intuitive Surgical from $566.00 to $571.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Finally, Evercore ISI increased their price objective on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Thirteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $595.95.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the completion of the sale, the executive vice president owned 353 shares in the company, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Gary S. Guthart sold 2,800 shares of the firm's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $495.24, for a total transaction of $1,386,672.00. Following the completion of the sale, the insider owned 18,520 shares of the company's stock, valued at $9,171,844.80. The trade was a 13.13% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,839 shares of company stock worth $7,896,972. 0.70% of the stock is currently owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.